LeMaitre Vascular (LMAT): Is the Stock Undervalued After Recent Slide?

LeMaitre Vascular (LMAT) has seen its stock price shift noticeably in recent weeks, prompting investors to take a closer look at the current valuation. Shares are down about 13% over the past 3 months, reflecting broader market trends and sector movements.

See our latest analysis for LeMaitre Vascular.

Looking at the bigger picture, LeMaitre Vascular’s share price has struggled to regain ground lately, following a steady slide for much of this year. While momentum has clearly faded in the short term, the company still boasts an impressive 3-year total shareholder return of over 80%. This contrast highlights how quickly sentiment can shift around both growth expectations and risk appetite, especially in specialty healthcare stocks like LMAT.

If you want to see which other healthcare stocks are seeing momentum or have compelling long-term stories, you can browse the full list with our healthcare discovery tool: See the full list for free.

With shares trading well below analyst targets and the company posting solid long-term growth, the key question now is clear: Is LeMaitre Vascular undervalued and offering a bargain, or is the market accurately pricing in its coming potential?

Most Popular Narrative: 20.8% Undervalued

LeMaitre Vascular’s last close price of $82.95 is well below the fair value suggested by the most widely followed narrative, which values shares at $104.78. With the market behind analyst projections, long-term catalysts are drawing more scrutiny.

Robust growth in international markets, particularly Europe and emerging regions, is being driven by new product launches (such as Artegraft and RestoreFlow) and ongoing regulatory approvals in countries like Germany, Ireland, Canada, Korea, and Singapore. These developments are establishing significant new revenue streams and supporting future revenue growth.

Read the complete narrative.

Want to know what gives this stock such a rich fair value? One of the key drivers is a future revenue outlook fueled by global expansion and a suite of next-generation products. The hook is a bold growth trajectory built into the numbers that is unlike what you see in most medtech forecasts. Curious to find out which game-changing assumptions are behind this compelling upside story? The full narrative unpacks it all.

Result: Fair Value of $104.78 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, any slowdown in organic demand or challenges in sustaining recent pricing power could quickly reverse the optimism that is currently driving LeMaitre Vascular’s valuation outlook.

Find out about the key risks to this LeMaitre Vascular narrative.

Another View: Market Multiples Tell a Different Story

While the fair value narrative points to upside, the latest ratio-based approach signals caution. LeMaitre Vascular is trading at 35.3 times earnings, noticeably higher than both the industry average of 28.9 and its own fair ratio of 17.6. This premium suggests the shares may be priced aggressively compared to peers and historical trends. Is the market layering in too much optimism, or does it know something the numbers do not?

See what the numbers say about this price — find out in our valuation breakdown.

Build Your Own LeMaitre Vascular Narrative

If you see the story differently or want to take a hands-on approach, you can dive into the data and shape your own perspective in just a few minutes. Do it your way

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding LeMaitre Vascular.

Looking for More Investment Ideas?

Don’t settle for just one opportunity when you could be ahead of the curve on several fronts. Let your next move be intentional and informed by the very best investment screens offered on Simply Wall Street.

• Tap into hidden value by checking out these 914 undervalued stocks based on cash flows, where overlooked companies show strong upside based on their cash flows and future prospects.
• Capture future growth potential by following these 25 AI penny stocks, which are riding the AI megatrend and innovating across industries.
• Boost your passive income stream by browsing these 15 dividend stocks with yields > 3%, featuring companies with consistent dividend yields above 3%.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com